Member Info for ziva

Hi, I’ve been watching these shares for sometime now and the thought crossed my mind there’s a lot of huge unknown late trades, (this is only my opinion) could it be possible that AXL are buying back their shares to put back in the treasury to protect the companies interests. Millions coming in and assets producing large quantities of oil. A person owning 16% + as a shareholder ( largest shareholder) if it was me I would protect the company that I have built. And is it possible thats why the results from ic-2 have not been released. If this were fact, the company would be protected from a takeover and the shareholders would benefit from a raise in share prices. As I say it’s only my opinion.

Rome was never built in a day, I fully agree with your way of thinking. To the future no one knows but hopefully this is a well run company that is capable of building a better aim listed company and I think long term can be very successful, only my opinion.

😉

When you look at a company like met1 up to 80+ percent gains on Friday and it’s going to take years before any mining takes place, I must be on a different planet MedPal are making cash turnover every month doesn’t make sense.

As I don’t like to get involved in politics on group chats, but on this occasion I’m going to fully agree labour are very anti business and couldn’t care less if small businesses survive or not🤬

Unlike a lot of aim companies on the stock exchange (oil, gas, minerals ect) we have a monthly cash flow that is advancing nicely. I certainly agree with lots of you guys on this group chat, that have done your own research and have a positive outlook on this company, that MedPal is a company going places now and in the future, but soon as results come out in near future all the bottom feeders will be on this chat group ramping & de- ramping . Don’t let it change your way of thinking about MedPal, after all how many times in 2/3 years when a share price has gone up massively and say I was in that in the beginning but sold 😔 Good luck to all you guys truly in MedPal

58+ trades is nothing and they mark it down!!!

I think the news feed will be Tuesday and another one in coming days.

I think they will split into 2 news feeds on different days, we don’t want all the good news in one 🤣🤣🤣

If 32000 prescriptions in February what sort of figures now( mind boggling)

In February 2026, the Remedi pharmacy business (operating as Remedi Solutions from leased premises in Runcorn, UK) was actively functioning and dispensing prescriptions, handling over 32,000 prescription items that month alone.The operation was in a transitional phase following its initial administration in late 2024. Here is the timeline of events surrounding that period:February 2026: Remedi operated under the oversight of MedPal Limited (a subsidiary of MedPal AI plc). MedPal was operating the facility and fulfilling thousands of NHS and private prescriptions monthly.April 2026: MedPal Limited officially acquired the Remedi pharmacy assets, trade, and business operations to further scale its digital pharmacy and healthcare operations.

I was doing a bit of research into the ins and outs of Remedi , our very smart director built a company specially to hold the lease for the acquired pharmacy , what a piece of engineering. And company name is New Performance Health Limited listed 26 march 2026 also sell medical products

Jason Drummond, Chief Executive Officer of MedPal AI, commented:

"For a total spend of less than half a million pounds we have secured an NHS dispensing hub in a strategically critical location with a patient book that NHS-verified data shows historically delivered over £10 million of annualised turnover. We have already proven at Swaffham that our reactivation strategy works. We are now running that same programme, at materially greater scale, across the Remedi book. Our pharmacy operations are growing rapidly, currently dispensing 42,000 items a month and rising, with a mapped path to pharmacy-level breakeven at 80,000 items a threshold the acquired Runcorn site alone comfortably exceeded throughout 2024"

This was copied from the RNS 29th April quote 42,000 and RISING ( the trading month was nearly over)

On 6 December 2024, Remedi entered into administration. In October 2025, Jason Drummond entered into a conditional sale and purchase agreement ("SPA") with the Administrators to acquire Remedi's trade and assets for which the Administrators (Nick Harris and Lucinda Coleman, of PKF Francis Clark), were paid £30,000 to secure the right. Under the terms of the SPA, Mr Drummond had the right to novate his interest in the SPA and his right to acquire the Remedi pharmacy business. Pursuant to the requirements of an S26 pharmacy licence, in order to preserve the existing trade and pharmacy licence, Medpal Limited was appointed as the Responsible Person to operate the pharmacy business. Since this time, MedPal Limited has accordingly already received some economic benefit.

Looks like we will could get a undate on sales from Remedi as well (economic benefits) 🤔

Universal Pharmacy Limited (UPL) was not a publicly traded entity and did not disclose its monthly turnover before collapsing. However, historical NHS prescription item records and subsequent corporate reporting outline the scale of its former operations:Prescription Volumes: At its peak in August 2024, the pharmacy dispensed 25,812 prescription items per month.Pre-Administration Activity: Dispensing figures dropped sharply prior to its administration in August 2025, with around 17,000 items dispensed monthly in April and May, before falling to under 4,000 items in June 2025. For a company trading for 14 years MedPal mashed them in 5 months. Just to prove growth rate on swaffham .

Only researching will benefit the wealthy 👊

Who knew, MedPal did !!!

Https://pharmacyinfocus.co.uk/pharmacy-business-outlook-2026-from-christie-co/

Just what Jason said (Amazon like)

Strengthen the price before releasing positive news, that’s good business ethic of a good company.

MedPal AI recently marked its entry into NHS pharmaceutical services by taking over a Distance Selling Pharmacy (DSP) contract in Norfolk and Waveney in November 2025. As the NHS shifts toward digital transformation, several contract areas are evolving, potentially opening opportunities for MedPal's AI-driven, robotic dispensing model.

AJ Bell

AJ Bell

+3

NHS Prescription Contract Trends & Renewals (2025-2027)

Distance Selling Pharmacy (DSP) Contracts: Following the General Pharmaceutical Council's (GPhC) cessation of issuing new DSP licenses in June 2025, existing DSP contracts—like the one acquired by MedPal—have become highly valuable "rare entry points". Opportunities now primarily exist through acquisitions or takeovers of distressed pharmacies, similar to MedPal's acquisition of Universal Pharmacy.

High-Tech Homecare Medicine Services: Contracts for specialized homecare medicine services are being tendered, with major suppliers including Sciensus, Lloyds Pharmacy Clinical Homecare, Healthnet Homecare, and others.

Local Enhanced Services (LCS) 2025-26: Numerous local contracts for services like addiction support, nicotine replacement, and specific medication reviews are awarded by Integrated Care Boards (ICBs). These are often awarded to local providers but represent a fragmented market where digital efficiency could provide an edge.

Community Pharmacy Framework (CPCF): Negotiations for 2026/27 are underway, with a push toward digital integration and "Pharmacy First" services.

GOV.UK

GOV.UK

+6

MedPal's Winning Opportunities

MedPal has a significant chance of winning or acquiring further contracts based on its "vertically integrated model".

Pharmacy Network

Pharmacy Network

Disruptive Efficiency: MedPal aims to process prescriptions for under £2, targeting the high-volume private and NHS market using robotic dispensing.

"Bargain" Acquisitions: MedPal has demonstrated success in acquiring distressed pharmacy assets, having acquired Universal Pharmacy and run Remedi Solutions.

Digital Focus: The 10-year NHS plan heavily emphasizes AI and digital transformation by 2028, aligning with MedPal’s core AI-driven app and pharmacy model.

Private-to-NHS Pipeline: With high demand for their private weight loss services and rapid early adoption, MedPal can scale its infrastructure to take on more NHS volumes.

Investegate

Investegate

+4

Key Focus Areas for MedPal:

ICB Contracts: Opportunities to partner with Integrated Care Boards looking for efficient pharmacy providers for specialized services.

Distressed Asset Takeovers: Identifying further pharmacies in administration that hold valuable DSP or

+2 MedPal AI recently marked its entry into NHS pharmaceutical services by taking over a Distance Selling Pharmacy (DSP) contract in Norfolk and Waveney in November 2025. As the NHS shifts toward digital transformation, several contract areas are evolving, potentially opening opportunities for MedPal's AI-driven, robotic dispensi